CN101670027B - 复方首乌口服液及其制备方法和质量检测方法 - Google Patents
复方首乌口服液及其制备方法和质量检测方法 Download PDFInfo
- Publication number
- CN101670027B CN101670027B CN2009103083575A CN200910308357A CN101670027B CN 101670027 B CN101670027 B CN 101670027B CN 2009103083575 A CN2009103083575 A CN 2009103083575A CN 200910308357 A CN200910308357 A CN 200910308357A CN 101670027 B CN101670027 B CN 101670027B
- Authority
- CN
- China
- Prior art keywords
- solution
- water
- oral liquid
- flower root
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 56
- 240000001341 Reynoutria japonica Species 0.000 title claims abstract description 43
- 235000018167 Reynoutria japonica Nutrition 0.000 title claims abstract description 43
- 150000001875 compounds Chemical class 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 238000003908 quality control method Methods 0.000 title abstract description 4
- 235000020374 simple syrup Nutrition 0.000 claims abstract description 7
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 7
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 7
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 7
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 6
- 235000008434 ginseng Nutrition 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 45
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 44
- 239000003814 drug Substances 0.000 claims description 42
- 229940079593 drug Drugs 0.000 claims description 28
- 239000000047 product Substances 0.000 claims description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 238000012360 testing method Methods 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 13
- 239000013558 reference substance Substances 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 10
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000004809 thin layer chromatography Methods 0.000 claims description 6
- 239000000341 volatile oil Substances 0.000 claims description 6
- 241000208340 Araliaceae Species 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 235000019640 taste Nutrition 0.000 claims description 4
- 238000004821 distillation Methods 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 238000001256 steam distillation Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- JAYVHSBYKLLDJC-DSNJPTTOSA-N (E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(O)C=C(O)C=C1\C=C\C1=CC=C(O)C=C1 JAYVHSBYKLLDJC-DSNJPTTOSA-N 0.000 claims description 2
- -1 1 hour Substances 0.000 claims description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 2
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000010282 Emodin Substances 0.000 claims description 2
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 claims description 2
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 claims description 2
- YEZWWUMWIFKEQM-UHFFFAOYSA-N O.OC.ClC(Cl)Cl.CCOC(C)=O Chemical compound O.OC.ClC(Cl)Cl.CCOC(C)=O YEZWWUMWIFKEQM-UHFFFAOYSA-N 0.000 claims description 2
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical class [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 claims description 2
- 230000000274 adsorptive effect Effects 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 2
- XRIVRYRXJYCJTQ-UHFFFAOYSA-N benzene;ethyl acetate;formic acid Chemical compound OC=O.CCOC(C)=O.C1=CC=CC=C1 XRIVRYRXJYCJTQ-UHFFFAOYSA-N 0.000 claims description 2
- 238000005660 chlorination reaction Methods 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 238000012850 discrimination method Methods 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 claims description 2
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000012567 medical material Substances 0.000 claims description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000011003 system suitability test Methods 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 claims 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 claims 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 claims 1
- 238000004811 liquid chromatography Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 32
- 210000003734 kidney Anatomy 0.000 abstract description 20
- 210000004369 blood Anatomy 0.000 abstract description 18
- 239000008280 blood Substances 0.000 abstract description 18
- 210000004185 liver Anatomy 0.000 abstract description 17
- 230000007812 deficiency Effects 0.000 abstract description 14
- 208000024891 symptom Diseases 0.000 abstract description 14
- 210000004556 brain Anatomy 0.000 abstract description 11
- 206010012289 Dementia Diseases 0.000 abstract description 7
- 230000036772 blood pressure Effects 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 4
- 230000036737 immune function Effects 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 244000205574 Acorus calamus Species 0.000 abstract 1
- 235000006480 Acorus calamus Nutrition 0.000 abstract 1
- 244000241872 Lycium chinense Species 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 241000208966 Polygala Species 0.000 abstract 1
- 244000292697 Polygonum aviculare Species 0.000 abstract 1
- 235000006386 Polygonum aviculare Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 230000006872 improvement Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000005728 strengthening Methods 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 6
- 208000031971 Yin Deficiency Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 206010067482 No adverse event Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 235000015961 tonic Nutrition 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 206010008088 Cerebral artery embolism Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000009189 diving Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 201000010849 intracranial embolism Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种中药制剂,即具有滋补肝肾,健脑益智功能的复方首乌口服液及制备方法和质量控制方法。由制何首乌266.7g,枸杞子200g,远志166.7g,石菖蒲133.3g,桑椹133.3g,人参66.7g,大枣33.3g,单糖浆360ml,苯甲酸钠2.7g,制成1000ml。经对235例患者临床观察,本品能明显改善痴呆、智力衰弱、记忆力减退病人的肝肾阴虚,心气不足等症状,并能提高智力,改善痴呆,对血压可能优良性调节作用,还可能具有降血脂、调节非特异性体液免疫功能的作用,对肝肾及血液系统无不良影响,床观察未见副作用,显效率62.55%,总有效率96.17%。久服可增加智力,延缓衰老,增强体质。
Description
技术领域
本发明涉及一种中药制剂,即具有滋补肝肾,健脑益智功能的复方首乌口服液及制备方法和质量控制方法。
背景技术
在现有技术中,随着科学的进步,人们对增加智能的要求愈加迫切,多种疾病(脑动脉硬化脑栓塞、高血压病,老年痴呆等症)的病后记忆力减退、老年性记忆减退、儿童智力低下及中、小学生都在寻求增加智能、改善记忆、缓解脑力疲劳之品。然而,目前国内外能增加智商效果可靠之品尚缺乏。
发明内容
本发明的目的是针对上述情况而提供一种针对智力减退、痴呆有疗效的复方首乌口服液及制备方法和质量控制方法。
本发明的技术解决方案是:复方首乌口服液包括以下重量原料药制成:何首乌(制)266.7g,枸杞子200g,远志166.7g,石菖蒲133.3g,桑椹133.3g,人参66.7g,大枣33.3g,单糖浆360ml,苯甲酸钠2.7g,制成1000ml。
祖国医学对人的精神思维活动有其独特的分类描述。与智力关系密切的,主要有心、肝、肾等脏。本方主药选用何首乌苦甘而涩,温而不燥。化阴生血固涩精气,善补肝肾,健筋骨,乌须发,向为补血益精之良药。《何首乌录》有“长筋益精,能食,益气力,长肤延年”的记载。构杞子味甘,气平,质地滋润,能补肝血,益肾精,扶阳气,壮筋骨,为养血补精之佳品。《本草经疏》说:“枸杞子润而滋补,兼能退热,而专于补肾,润肺,生津,益气。为肝肾真阴不足,劳乏内热,补益之要药。二药并列为君药,功专补益肝肾,添充髓海以健脑元神之府。臣以桑椹子甘酸微寒,清凉润降,能滋肾水,补肝血,生津液,润心肺,乌须发。《本草经疏》说:“桑椹,甘寒益血而除热,为凉血,补血,益阴之药。……故魂安而神自清宁,神明则聪明内发”的记述。远志气温味苦,善交通心肾,使水火相济,能益心气,安心神,止惊悸开智慧。《本经》说“治咳逆伤中,补不足,除邪气,利九窍,益智慧,耳目聪明,不忘”。石菖蒲辛温,能开心窍,通心神,豁痰涎,利清阳。《别录》说:“聪耳目,益心智”,三臣药辅助君药心肝肾兼顾,可增强扶虚益损之功,佐以人参大补元气,特益脾肺,善振脾阳,资化源,益肺气,充百脉,生津止渴,宁神益智。《本经》载: “补五脏,安精神,定魂魄,止惊悸,除邪气,明目,开心益智。”得配君臣药不但三阴并理,而且有益脾肺,脾胃健运则谷化精微气血生,肺主诸脏之气,肺气旺则余脏受荫,是以人参协同君臣助益五脏生化之机则泉源有自,从而精气神充沛,记忆力增强,智力当可敏捷。使以大枣不但合同群药补脾益气,养血安神,并具“和百药”(《本经》)之能。诸药合用,共奏补益精髓,健脑益智之功效。
制法:以上七味,取石菖蒲、桑椹用水蒸汽蒸馏法提取挥发油,蒸馏后的水溶液另器收集;药渣及其余何首乌等五味加8、6、6倍量水煎煮三次,每次1.5小时,合并煎液,滤过,滤液与上述水溶液合并,浓缩至450ml,加乙醇至醇浓度为60%,搅拌,静置24小时,滤过,减压浓缩至相对密度为1.5(80℃)的稠膏,加水稀释至450ml,相对密度为1.20-1.25(50℃);置-5℃冷冻24小时,室温溶化后,滤过,加单糖浆360ml,苯甲酸钠2.7g及上述挥发油,再加水至1000ml,搅拌,滤过,分装,灭菌,即得。
上述制剂不限于此,按上述各药用原料与制药上常用的药用载体、添加剂或辅料还可以混合制成片剂、胶囊剂(软胶囊剂)、颗粒剂、散剂、丸剂、液体制剂或其它常规制剂。
药理实验
1、经跳台法、食物迷宫法和电迷宫法观察复方首乌口服液对学习记忆的影响。实验证明本品具有抗樟柳碱所致的记忆获得障碍的作用,增加大、小鼠方向辨别能力。说明复方首乌口服液具有促进学习记忆作用。
2,经肾虚动物模型实验观察了复方首乌口服液在跳台中错误反应次数低抗乏氧和抗疲劳的能力。结果表明本品能对抗因肾虚所致小鼠学习记忆减退,增强抗氧、抗疲劳能力。
3、复方首乌口服液能增加大、小鼠脑DNA、RNA和蛋白质含量。复方首乌口服液增智作用与脑内核酸,蛋白质含量有关。
4,复方首乌口服液能增加大鼠脑内NA和DA含量。说明复方首乌口服液增智作用与脑内单胺类递质改变有关。
5、复方首乌口服液能降低血浆和肝脏中LPO含量,增加红细胞中SOD活性,降低脑组织中MA0-B含量,说明本品具有抗衰老作用。
毒理学研究:1、急性毒性实验:给20只小鼠灌胃3.33g/ml的复方首乌口服液,每次0.7ml/只,24小时内灌胃三次,累计剂量为349.66g/kg相当于临床用药量的874.23倍。给药后观察7日,小鼠饮食正常,毛色光亮,活动自如,体重增加,呼吸平稳,取其它不良反应和死亡。说明本品毒性甚小。2、长期毒性实验:复方首乌口服液40、20和10ml/kg给大鼠灌胃,每日1次,连续90日,结果末见动物体重、血象和肝肾功能的异常改变。病理检查与 对照组比较也无显著差异。结合急性毒性实验说明本品毒性小。
功能与主治:滋补肝肾,健脑益智。用于心、肝、肾阴虚引起的头晕目眩、健忘失眠、腰膝酸软、神疲乏力等症。
用法与用量:口服,一次10ml,每日三次。
本发明的优点是:1、经临床对235例临床观察,本品不仅能明显改善痴呆、智力衰弱、记忆力减退病人的肝肾阴虚,心气不足等症状,并能提高智力,改善痴呆,对血压可能优良性调节作用,还可能具有降血脂、调节非特异性体液免疫功能的作用,对肝肾及血液系统无不良影响,床观察末见副作用,显效率62.55%,总有效率96.17%。2、久服可增加智力,延缓衰老,增强体质。
下面将结合实施例对本发明的实施方式作进一步详细描述。
具体实施方式
实施例1
复方首乌口服液由以下重量原料药制成:制何首乌266.7g,枸杞子200g,远志166.7g,石菖蒲133.3g,桑椹133.3g,人参66.7g,大枣33.3g,单糖浆360ml,苯甲酸钠2.7g,制成1000ml。
实施例2
复方首乌口服液制备方法:以上七味,取石菖蒲、桑椹用水蒸汽蒸馏法提取挥发油,蒸馏后的水溶液另器收集;药渣及其余何首乌等五味加8、6、6倍量水煎煮三次,每次1.5小时,合并煎液,滤过,滤液与上述水溶液合并,浓缩至450ml,加乙醇至醇浓度为60%,搅拌,静置24小时,滤过,减压浓缩至相对密度为1.5(80℃)的稠膏,加水稀释至450ml,相对密度为1.20-1.25(50℃);置-5℃冷冻24小时,室温溶化后,滤过,加单糖浆360ml,苯甲酸钠2.7g及上述挥发油,再加水至1000ml,搅拌,滤过,分装,灭菌,即得。
实验例1
复方首乌口服液的鉴别方法
该方法中包括如下任一种或几种组合:
(1)取本品50ml,加乙醚提取2次,每次20ml,弃去乙醚液,用水饱和的正丁醇提取3次,每次30ml,合并正丁醇液,浓缩至约30ml,用正丁醇饱和的2%氢氧化钠溶液提取2次,每次30ml,弃去碱液,再用正丁醇饱和的水30ml提取,弃去水层,蒸干,残渣加甲醇lml使溶解,作为供试品溶液;另取人参皂苷Rg1对照品,加甲醇制成每lml含lmg的溶液,作为对照品溶液;照薄层色谱法(中国药典2005年版一部附录VI B)试验,吸取上述两种溶液各6μl ,分别点于同一以0.3%羧甲基纤维素钠为粘合剂的硅胶G薄层板上,以氯仿-醋酸乙酯-甲醇-水(15∶40∶22∶10)10℃以下放置的下层溶液为展开剂,展开,取出,晾干,喷以10%硫酸乙醇溶液,以105℃烘至斑点显色清晰,日光下检视;供试品色谱中,在与对照品色谱相应的位置上,显相同颜色的斑点。
(2)取本品50ml,加乙醚提取2次,每次20ml,弃去乙醚液,用水饱和的正丁醇提取3次,每次30ml,合并正丁醇液,浓缩至约30ml,用正丁醇饱和的氨试液提取2次,每次30ml,弃去碱液,蒸干,残渣加甲醇lml使溶解,作为供试品溶液;另取远志对照药材5g,加水煎煮2小时,放冷,滤过,滤液浓缩至约15ml,用水饱和正丁醇提取2次,每次15ml,合并正丁醇液,蒸干,残渣加甲醇1ml使溶解,作为对照药材溶液;照薄层色谱法(中国药典2005年版一部附录VI B)试验,吸取上述两种溶液各6μl,分别点于同一以0.3%羧甲基纤维素钠为粘合剂的硅胶G薄层板上,以苯-醋酸乙酯-甲酸(13∶4∶0.5)为展开剂,展开,取出,晾干,置紫外光灯(365nm)下检视;供试品色谱中,在与对照药材色谱相应的位置上,显相同颜色的荧光斑点。
(3)取本品50ml,加盐酸1ml,回流提取1小时,立即冷却,用乙醚提取2次,每次50ml,合并提取液,蒸干,残渣加氯仿2ml使溶解,作为供试晶溶液;另取大黄素对照品,加氯仿制成每1ml含1mg的溶液,作为对照品溶液;照薄层色谱法(中国药典2005年版一部附录VIB)试验,吸取上述两种溶液各5μl,分别点于同一以0.3%羧甲基纤维素钠为粘合剂的硅胶G薄层板上,以石油醚(60-90℃)-醋酸乙酯-甲酸(13∶5∶1)的上层溶液为展开剂,展开,取出,晾干,置紫外光灯(365nm)下检视;供试品色谱中,在与对照品色谱相应的位置上,显相同的橙黄色荧光斑点;置氨气中熏后,日光下检视,斑点变为红色。
实验例2
复方首乌口服液的含量测定方法
照高效液相色谱法(中国药典2005年版一部附录VID)测定;
色谱条件与系统适用性试验:用十八烷基硅烷键合硅胶为填充剂;乙腈-水(25∶75)为流动相;检测波长为320nm;理论板数按2,3,5,4’-四羟基二苯乙烯-2-O-β-D-葡萄糖苷峰计算应不低于2000。
对照溶液的制备:精密称取2,3,5,4’-四羟基二苯乙烯-2-O-β-D葡萄糖苷对照品适量,加稀乙醇制成每1ml含0.1mg的溶液,即得。
供试品溶液的制备:精密量取本品1ml,置D101大孔吸附树脂柱(内径约1.5cm,填充高度10cm)上,以每分钟2.0ml的流速洗脱,弃去水洗脱液,用稀乙醇洗脱,弃去稀乙醇洗脱液7 -9ml,收集洗脱液100ml,蒸干,残渣加稀乙醇溶解,置10ml量瓶中,加稀乙醇稀释至刻度,摇匀,即得。
测定法分别精密吸取对照品溶液和供试品溶液各5μl,注入液相色谱仪,测定,即得。
本品每10ml含2,3,5,4’-四羟基二苯乙烯-2-O-β-D-葡萄糖苷(C20H22O9)计,不得少于6.0mg。
实验例3
复方首乌口服液临床报告
复方首乌口服液增智保健作用临床观察总结——吉林省中医中药研究院
为观察验证复方首乌口服液的增智保健作用,对235例中医辨证为肝肾阴虚、心气不足或兼痰浊阻窍的具有不同程度低智、记忆力明显减退的病人进行临床观察,取得较好的疗效,现报告如下:
1、临床资料
本组235例,其中男性156例,女性79例:年龄:40岁15例,40-49岁19例,50-59岁45例,60岁以上156例;病程:1年40例,1-3年109例,4-5年37例,6年49例。
2观察方法
(1)诊断与疗效评定标准
诊断与疗效评定标准均按照全国中西医结合老年病和虚证专业委员会《中医虚证辨证参考标准》的肾虚、肝虚、心虚、阴虚证,参照《老年呆病的诊断、辨证分型及疗效评定标准》进行判定。症状按轻:+,中:++,重:+++填表。
疗效评定标准:
显效:主要症状基本恢复,神志清醒,定向健全,回答问题正确,反应灵敏,生活自理,能进行一般的社会活动。主症消失(重+++→轻+或重+++、中++、轻+→-)主要症状3项显效+2项好转,4项显效+1项无效,2项显效+3项好转。
有效:主要精神症状有所减弱,或部分消失、生活基本自理,回答问题基本正确,但反应迟钝,智力与人格仍有部分障碍。主症减轻(+++→++,++→+)主要症状1项显效十2项好转,3项以上好转。
无效:主要症状无改变,或病情有发展,生活不能自理,回答问题不正确,神志痴呆。
(2)病例选择:凡符合中医辨证为肝肾阳虚,心气不足或兼痰浊阻窍[包括西医诊断为老年性痴呆、脑血管,瞒呆(多发性梗塞性痴呆及脑出血、脑.血栓形成、脑栓塞后痴呆)] 及混合性痴呆、脑叶萎缩症,正压性脑积水、脑淀粉祥血管病,植物神经功能失调引起的智力减逊的门诊和住院病人;无其他严重疾病影响疗效观察者;均可作为观察对象。
(3)观察药物:复方首乌口服液由通化白山药业股份有限公司提供,用法:每次口服10ml。每日3次,30天为1疗程。用本药前三周停用有关滋补强壮药物,用本药期间禁用其他有关药物。
(4)统计方法:采用配对t检验和秩和检验进行统计学分析。
3、观察结果
(1)复方首乌口服液对症状的改善
表1复方首乌口服液对症状的改善
失眠健忘 | 智力障碍 | 头晕目眩 | |
+++ ++ + - | +++ ++ + - | +++ ++ + - | |
用药前 | 78 91 59 7 | 34 75 112 14 | 59 110 55 11 |
用药后 | 2 31 104 98 | 0 24 79 132 | 3 20 96 116 |
P值 | <0.01(u=13.86) | <0.01(u=14.64) | <0.01(u=14.02) |
腰膝酸软 | 神疲乏力 | 手足心热 | 心悸气短 |
+++ ++ + - | +++ ++ + - | +++ ++ + - | +++ ++ + - |
36 105 73 30 | 33 93 90 13 | 26 41 65 101 | 19 61 75 80 |
1 15 77 102 | 2 21 77 133 | 10 20 32 173 | 0 18 62 155 |
<0.01(u=13.01) | <0.01(u=13.50) | <0.01(u=7.16) | <0.01(u=3.34) |
由上表可见,复方首乌口服液能明显改善肝肾阴虚、心气不足等症状。
(2)复方首乌口服液对智能的影响
表2复方首乌口服液对智能的影响X-±S分
由表2可见用药后智能提高,痴呆改善。说明复方首乌口服液有较好的增智作用。
(3)复方首乌口服液对血红蛋白,白细胞的影响
表3复方首乌口服液对血红蛋白,白细胞的影响X-±S
n | 血红蛋白(g/L) | 白细胞数(×109/L) |
用药前230 | 126.81±17.59 | 8.02±2.91 |
用药后230 | 129.24±16.08 | 7.63±1.85 |
P值 | <0.05(t=2.54) | <0.05(t=2.49) |
由表3可见用药后血红蛋白有所提高,白细胞有所下降.但均在正常范围波动,故可认为对血液系统无不良影响。
(4)复方首乌口服液对血压的影响
表4复方首乌口服液对血压的影响X±S KPa
n | 收缩压 | 舒张压 |
用药前230 | 18.98±3.36 | 11.86±1.70 |
用药后230 | 18.17±3.07 | 11.52±1.37 |
P值 | <0.01(t=8.03) | <0.01(t=15.33) |
由表4可见用药后血压有所下降,但波动在正常范围,提示本品无血压升高的副作用,可能对血压有一定的良性调节作用或一定的降压作用。
(5)复方首乌口服液对血脂的影响
表5复方首乌口服液对血脂的影响X+S mmol/L
n | 胆固醇 | 三酸甘油酯 |
用药前58 | 4.69±1.14 | 1.05±0.81 |
用药后58 | 3.89±1.01 | 0.73±0.44 |
P值 | <0.01(t=5.93) | <0.01(t=3.31) |
由表5可见用启智灵后血胆固醇、三酸甘油脂有所下降,提示本品可能有一定的降脂作用。
(6)复方首乌口服液对免疫球蛋白的影响
表6复方首乌口服液对免疫球蛋白的影响X±S g/L
n | IgG | IgA | IgM |
用药前82 | 11.30±2.38 | 1.37±0.66 | 1.38±0.43 |
用药后82 | 11.69±2.27 | 1.76±0.50 | 1.46±0.40 |
P值 | <0.05(t=1.83) | >0.10(t=30.70) | >0.10(t=1.63) |
由表6可见服用复方首乌口服液后兔疫球蛋白较用药前有所提高,其中IgG明显高于用药前,故本品可能有调节非特性体液免疫功能的作用。
(7)复方首乌口服液对尿常规肝功能的影响
经235例临床观察用本药后尿常规、肝功能较用药前无异常改变,可见本药对肝、肾功能无不良影响。另外也未见其他副作用。
(8)总疗效
235例中显效147例,显效率62.55%,有效79例,有效率33.62%,总有效率96.17%,无效9例,无效率3.83%。
4、小结
经我们对235例临床观察,本品不仅能明显改善痴呆、智力衰弱、记忆力减退病人的肝肾阴虚,心气不足等症状,并能提高智力,改善痴呆,对血压可能优良性调节作用,还可能具有降血脂、调节非特异性体液免疫功能的作用,对肝肾及血液系统无不良影响,床观察末见副作用,显效率62.55%,总有效率96.17%。本品服用携带方便,药源丰富易得,价格低廉,疗效高,可为增智保健佳品,值得推广应用。
Claims (3)
1.一种复方首乌口服液,其特征在于由以下重量原料药制成1000ml:制何首乌266.7g,枸杞子200g,远志166.7g,石菖蒲133.3g,桑椹133.3g,人参66.7g,大枣33.3g,单糖浆360ml,苯甲酸钠2.7g;制备方法是:取石菖蒲、桑椹用水蒸汽蒸馏法提取挥发油,蒸馏后的水溶液另器收集;药渣及其余何首乌等五味加8、6、6倍量水煎煮三次,每次1.5小时,合并煎液,滤过,滤液与上述水溶液合并,浓缩至450ml,加乙醇至醇浓度为60%,搅拌,静置24小时,滤过,减压浓缩至80℃下测定相对密度为1.5的稠膏,加水稀释至450ml,50℃下测定相对密度为1.20-1.25;置-5℃冷冻24小时,室温溶化后,滤过,加单糖浆360ml,苯甲酸钠2.7g及上述挥发油,再加水至1000ml,搅拌,滤过,分装,灭菌,即得。
2.如权利要求1所述的复方首乌口服液的鉴别方法,其特征在于该方法中包括如下任一种或几种组合:
(1)取本品50ml,加乙醚提取2次,每次20ml,弃去乙醚液,用水饱和的正丁醇提取3次,每次30ml,合并正丁醇液,浓缩至约30ml,用正丁醇饱和的2%氢氧化钠溶液提取2次,每次30ml,弃去碱液,再用正丁醇饱和的水30ml提取,弃去水层,蒸干,残渣加甲醇1ml使溶解,作为供试品溶液;另取人参皂苷Rg1对照品,加甲醇制成每1ml含1mg的溶液,作为对照品溶液;按照中国药典2005年版一部附录ⅥB中薄层色谱法试验,吸取上述两种溶液各6μl,分别点于同一以0.3%羧甲基纤维素钠为粘合剂的硅胶G薄层板上,以氯仿-醋酸乙酯-甲醇-水=15∶40∶22∶10,10℃以下放置的下层溶液为展开剂,展开,取出,晾干,喷以10%硫酸乙醇溶液,以105℃烘至斑点显色清晰,日光下检视;供试品色谱中,在与对照品色谱相应的位置上,显相同颜色的斑点;
(2)取本品50ml,加乙醚提取2次,每次20ml,弃去乙醚液,用水饱和的正丁醇提取3次,每次30ml,合并正丁醇液,浓缩至约30ml,用正丁醇饱和的氨试液提取2次,每次30ml,弃去碱液,蒸干,残渣加甲醇1ml使溶解,作为供试品溶液;另取远志对照药材5g,加水煎煮2小时,放冷,滤过,滤液浓缩至约15ml,用水饱和正丁醇提取2次,每次15ml,合并正丁醇液,蒸干,残渣加甲醇1ml使溶解,作为对照药材溶液;按照中国药典2005年版一部附录ⅥB中薄层色谱法试验,吸取上述两种溶液各6μl,分别点于同一以0.3%羧甲基纤维素钠为粘合剂的硅胶G薄层板上,以苯-醋酸乙酯-甲酸=13∶4∶0.5为展开剂,展开,取出,晾干,置365nm紫外光灯下检视;供试品色谱中,在与对照药材色谱相应的位置上,显相同颜色的荧光斑点;
(3)取本品50ml,加盐酸1ml,回流提取1小时,立即冷却,用乙醚提取2次,每次50ml,合并提取液,蒸干,残渣加氯仿2ml使溶解,作为供试品溶液;另取大黄素对照品,加氯仿制成每1ml含1mg的溶液,作为对照品溶液;按照中国药典2005年版一部附录ⅥB中薄层色谱法试验,吸取上述两种溶液各5μ1,分别点于同一以0.3%羧甲基纤维素钠为粘合剂的硅胶G薄层板上,以石油醚-醋酸乙酯-甲酸=13∶5∶1的上层溶液为展开剂,展开,取出,晾干,置365nm紫外光灯下检视;供试品色谱中,在与对照品色谱相应的位置上,显相同的橙黄色荧光斑点;置氨气中熏后,日光下检视,斑点变为红色。
3.如权利要求1所述的复方首乌口服液的含量测定方法,其特征在于方法如下:
按照中国药典2005年版一部附录VID中的高效液相色谱法测定;
色谱条件与系统适用性试验:用十八烷基硅烷键合硅胶为填充剂;乙腈-水=25∶75为流动相;检测波长为320nm;理论板数按2,3,5,4’-四羟基二苯乙烯-2-O-β-D-葡萄糖苷峰计算应不低于2000;
对照溶液的制备:精密称取2,3,5,4’-四羟基二苯乙烯-2-O-β-D-葡萄糖苷对照品适量,加稀乙醇制成每1ml含0.1mg的溶液,即得;
供试品溶液的制备:精密量取本品1ml,置D101大孔吸附树脂柱上,以每分钟2.0ml的流速洗脱,弃去水洗脱液,用稀乙醇洗脱,弃去稀乙醇洗脱液7-9ml,收集洗脱液100ml,蒸干,残渣加稀乙醇溶解,置10ml量瓶中,加稀乙醇稀释至刻度,摇匀,即得;
测定法分别精密吸取对照品溶液和供试品溶液各5μl,注入液相色谱仪,测定,即得;
本品每10ml含2,3,5,4’-四羟基二苯乙烯-2-O-β-D-葡萄糖苷(C20H22O9)计,不得少于6.0mg。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009103083575A CN101670027B (zh) | 2009-10-16 | 2009-10-16 | 复方首乌口服液及其制备方法和质量检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009103083575A CN101670027B (zh) | 2009-10-16 | 2009-10-16 | 复方首乌口服液及其制备方法和质量检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101670027A CN101670027A (zh) | 2010-03-17 |
CN101670027B true CN101670027B (zh) | 2011-06-08 |
Family
ID=42017583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009103083575A Active CN101670027B (zh) | 2009-10-16 | 2009-10-16 | 复方首乌口服液及其制备方法和质量检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101670027B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104950069B (zh) * | 2015-06-23 | 2016-08-24 | 南京海昌中药集团有限公司 | 一种解郁顺心片质量检测方法 |
CN106248841A (zh) * | 2016-08-29 | 2016-12-21 | 贵州信邦制药股份有限公司 | 风湿宁药酒中制何首乌的含量测定方法 |
CN108404021A (zh) * | 2018-05-29 | 2018-08-17 | 郑州大学第附属医院 | 一种用于防治老年认知功能障碍的中药组合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1256896A (zh) * | 1998-12-16 | 2000-06-21 | 南析 | 一种鲜果汁饮料及制备方法 |
CN1279073A (zh) * | 2000-04-17 | 2001-01-10 | 李熙德 | 一种抗衰老的中药 |
-
2009
- 2009-10-16 CN CN2009103083575A patent/CN101670027B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1256896A (zh) * | 1998-12-16 | 2000-06-21 | 南析 | 一种鲜果汁饮料及制备方法 |
CN1279073A (zh) * | 2000-04-17 | 2001-01-10 | 李熙德 | 一种抗衰老的中药 |
Non-Patent Citations (4)
Title |
---|
周宝宽.抗疲劳防治亚健康中药整理与研究.《中华中医药学刊》.2008,第26卷(第1期),193-195. * |
张秋红等.大黄素成分的薄层分析条件综述.《时珍国医国药》.2000,第11卷(第4期),372-373. * |
徐桂花等.TLC法测定人参固本口服液中人参皂苷Rg_1的含量.《齐鲁药事》.2006,第25卷(第6期),345-346. * |
金阳.益脑胶囊质量标准的改进.《华西药学杂志》.2006,第21卷(第6期),599-601. * |
Also Published As
Publication number | Publication date |
---|---|
CN101670027A (zh) | 2010-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101164586B (zh) | 一种治疗阳痿的药物组合物及其制备方法 | |
CN101095751B (zh) | 具有祛黄褐斑、改善营养性贫血的药物组合物及制备方法 | |
CN101485796B (zh) | 治疗失眠的中药组合物及其制备方法 | |
CN102102079B (zh) | 一种降压食醋及其制备方法 | |
CN102397462A (zh) | 一种用于抗衰老的口服液及其制备方法和质量控制方法 | |
CN101670027B (zh) | 复方首乌口服液及其制备方法和质量检测方法 | |
CN109298125A (zh) | 一种健脾益肾药酒的薄层色谱检测方法 | |
CN103990013B (zh) | 一种尿道清药剂及其制备方法 | |
CN104840866A (zh) | 一种健脾产品及其检测方法 | |
CN102961595B (zh) | 一种温肾助阳的药物组合物及其制备方法和制剂 | |
CN104274789A (zh) | 一种治疗抑郁的中药组合物 | |
CN101869680B (zh) | 滋肾益精、补脑安神的组合物的新用途 | |
CN101966241A (zh) | 一种治疗心脑血管疾病的药物组合物的检测方法 | |
CN100482254C (zh) | 文冠果子仁有效部位的提取方法 | |
CN104873687A (zh) | 一种治疗儿童注意力缺陷多动障碍的中药组合物 | |
CN100400075C (zh) | 一种补气养血药物组合物及其制备方法 | |
CN100418562C (zh) | 一种治疗脾肾两虚症的药物组合物及其制备方法和质量控制方法 | |
CN101700270A (zh) | 一种用于神经衰弱的中药组合物及其制备方法和质量控制方法 | |
CN104605051B (zh) | 双麻杜仲叶茶和制法 | |
CN101564494B (zh) | 一种中药组合物的用途 | |
MX2010005839A (es) | Composiciones farmaceuticas para tratar la ansiedad. | |
CN102266428A (zh) | 抗衰老中药组合物及其制备方法和应用 | |
CN105012864A (zh) | 盐酸米安色林新晶型及其检测方法和应用 | |
CN105663053A (zh) | 无糖型通脉颗粒及其制备方法 | |
CN104352973A (zh) | 一种用于产后抑郁的中成药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170424 Address after: 134100 Tonghua, Sichuan Province, Tonghua Qu Chuan Development Zone, Jilin Patentee after: Tonghua Baishan Pharmaceutical Ltd Address before: 134100 Jilin County, Tonghua Bay Bay Development Zone Tonghua Bai Shan pharmaceutical Limited by Share Ltd Patentee before: Hua Yuqiang |
|
TR01 | Transfer of patent right |